据报俄罗斯或成中国境外首个注册康希诺(06185.HK)疫苗国家
《彭博通讯社》报道,康希诺生物(06185.HK)新冠疫苗的俄罗斯合作夥伴Petrovax Pharm希望俄国当局尽快注册该疫苗,或成该款疫苗首次在中国境外获得接种批准。Petrovax由俄罗斯首富Vladimir Potanin持有,公司医疗部门负责人Nikolay Dodonov表示,所有注册流程都已完成,预计数天内就将获得注册认证。
康希诺疫苗目前在进行三期试验,并在中国获得了紧急使用授权,但至今疫苗接种仅用於中国军人。Dodonov表示,去年8月Petrovax获得康希诺新冠疫苗在当地进行三期试验的许可,11月申请注册。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.